Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18180482 | 1.00 | KISS1R (0.43) | KISS1RFOLH1EPHX1SIRT6SIRT1 | |
| SCHEMBL13271777 | 0.87 | KISS1R (0.42) | KISS1RFOLH1EPHX1SIRT6SIRT1 | |
| SCHEMBL26743887 | 0.87 | KISS1R (0.35) | KISS1RFOLH1EPHX1SIRT6SIRT1 | |
| SCHEMBL15981311 | 0.87 | KISS1R (0.41) | KISS1RFOLH1SIRT6SIRT1MMP3 | |
| SCHEMBL27021702 | 0.86 | KISS1R (0.39) | KISS1R | |
| SCHEMBL19293337 | 0.86 | EPHX1 (0.47) | KISS1REPHX1SIRT6SIRT1 | |
| SCHEMBL2628433 | 0.86 | EPHX1 (0.42) | KISS1REPHX1SIRT6SIRT1CPB2 | |
| SCHEMBL26743889 | 0.85 | FOLH1 (0.43) | KISS1RFOLH1EPHX1CPB2KDM4A | |
| SCHEMBL27051308 | 0.84 | ALOX15 (0.41) | FOLH1SIRT6SIRT1MMP3MMP9 | |
| SCHEMBL26003106 | 0.84 | KISS1R (0.35) | KISS1RFOLH1EPHX1SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022022360-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THERFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
| EP-3210998-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20160310612-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEATTLE GENETICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310612-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | EGFR, HDGF, CD47 | KISS1R 1204/4885FOLH1 323/4885EPHX1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.